Preclinical protein platform play Envoy Therapeutics got taken out by Takeda this week for up to $140 million. That magical “up to” typical...

by Michael Boss It is astonishing when nine very smart people get it so wrong. I refer to the US Supreme Court decision in Mayo v. Prome...

The Food & Drug Administration's public health alert on Plavix is, as we point out in "The Pink Sheet" DAILY , a nice boos...

Merck sees itself as a leader in biomarker-based drug development. "We are toward the extreme end" of peer companies in the field,...

Translating the vision of personalized medicine into reality is no simple matter, but here's an obstacle we hadn't considered before...

Rare diseases have often been the starting point for breakthroughs in medicine and biology: Oliver Sachs, for one, has made a career out of ...

Better late than never. Readers of IN VIVO Blog responded to a previous post on whether proponents of personalized medicine can also be su...

The drug industry is breathing a sigh of relief now that Janet Woodcock has permanently assumed the role as head of FDA's drug center. B...

So now, even Ted Kennedy is talking about personalized medicine. The Dean of the Senate stopped by a policy breakfast put together by The Hi...

"Industry should take on the burden of showing the value of new technologies in terms of relative costs and benefits to the Federal gov...

Autumn's here, and the NFL is back. IN VIVO Blog's contingent of Philadelphia Eagles fans is predictably feeling a little uneasy ab...

There was little attention paid to last week's paper suggesting that PPAR delta agonists might be used to prevent the cardiovascular sid...